Bezlotoxumab is a monoclonal antibody medication used to treat complications of Clostridium difficile infection (CDI). It is given as an intravenous (IV) infusion, typically for 10 to 60 minutes. It works by neutralizing C. difficile toxins A and B and reducing recurrence of CDI. It is used in combination with other antibiotics. Bezlotoxumab does not treat the underlying cause of CDI, but it can reduce the risk of recurrence and reduce the need for additional treatment.
Bezlotoxumab, sold under the brand name Zinplava, is a human monoclonal antibody used specifically to reduce the recurrence of Clostridioides difficile (C. Diff) infections in adults and children over the age of one.
Here's a breakdown of Bezlotoxumab:
What it's used for:
- Preventing recurrence of C. Diff infections: Bezlotoxumab is not a treatment for C. Diff itself, but rather a preventive measure for those at high risk of recurrence after receiving standard antibiotic treatment for the initial infection.
How it works:
- C. Diff bacteria produce toxins, specifically toxin A and B, that contribute to the symptoms of the infection like diarrhea and inflammation.
- Bezlotoxumab acts by binding specifically to toxin B, neutralizing its effects, and preventing it from causing further damage to the intestines.
Key points to remember:
- Bezlotoxumab is administered as a single intravenous (IV) infusion over 60 minutes during ongoing antibiotic treatment for C. Diff.
- It is not a substitute for antibiotics and should be used in conjunction with standard C. Diff treatment.
- Safety considerations: Bezlotoxumab has been associated with an increased risk of heart failure in some studies, so it's crucial to discuss your individual risk factors with your doctor before receiving this medication.